The Korea Ministry of Food and Drug Safety granted marketing approval for Invossa-K Inj., the world’s first cell and gene therapy for degenerative arthritis.
Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration accepted its supplemental New Drug Application to include an indication for Sprycel (dasatinib) to treat children with Philadelphia chromosome-positive chronic phase chronic myeloid leukemia, as well as a powder for oral suspension formulation of Sprycel. The application is under priority review with an action date of November 9, 2017.
The fact that the European Medicines Agency again pushed back the deadline for ISO IDMP (Identification of Medicinal Products) compliance has not stopped the life sciences technology and services industry from promoting IDMP software and solutions.
lnylam Pharmaceuticals Inc., the leading RNAi therapeutics company, and Sanofi Genzyme, the specialty care global business unit of Sanofi, announced the initiation of the ATLAS Phase 3 clinical program for fitusiran.
Intouch Solutions announces the promotion of Peter Weissberg to vice president of market access.
The Fishawack Group of Companies – one of the largest independent medical communications organizations – acquired the Carling Group of Companies based in San Diego, including Carling Communications and MCME Global. Carling Communications is the first agency in the Fishawack Group to be focused entirely on healthcare marketing, while MCME Global specializes in medical education.
AgileHealthInsurance.com released the results of a nationwide poll that revealed an overwhelming majority of Americans desire additional health plan choices alongside Obamacare.
A definitive merger agreement was signed under which the shareholders of privately held Innovate Biopharmaceuticals Inc. will become the majority owners of Monster Digital Inc. Subject to shareholder approval, the combined company will advance a late-stage drug for celiac disease, which Innovate believes is a significant unmet medical need, into expected Phase 3 clinical trials.
